182 related articles for article (PubMed ID: 37646663)
1. MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and
Rodrigues JM; Hollander P; Schmidt L; Gkika E; Razmara M; Kumar D; Geisler C; Grønbæk K; Eskelund CW; Räty R; Kolstad A; Sundström C; Glimelius I; Porwit A; Jerkeman M; Ek S
Haematologica; 2024 Apr; 109(4):1171-1183. PubMed ID: 37646663
[TBL] [Abstract][Full Text] [Related]
2. MYC overexpression correlates with MYC amplification or translocation, and is associated with poor prognosis in mantle cell lymphoma.
Choe JY; Yun JY; Na HY; Huh J; Shin SJ; Kim HJ; Paik JH; Kim YA; Nam SJ; Jeon YK; Park G; Kim JE
Histopathology; 2016 Feb; 68(3):442-9. PubMed ID: 26100211
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma.
Jing C; Zheng Y; Feng Y; Cao X; Xu C
Sci Rep; 2021 Jun; 11(1):11896. PubMed ID: 34099776
[TBL] [Abstract][Full Text] [Related]
4. High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival.
Yi S; Zou D; Li C; Zhong S; Chen W; Li Z; Xiong W; Liu W; Liu E; Cui R; Ru K; Zhang P; Xu Y; An G; Lv R; Qi J; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Dec; 6(39):42362-71. PubMed ID: 26517511
[TBL] [Abstract][Full Text] [Related]
5. The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index.
Slotta-Huspenina J; Koch I; de Leval L; Keller G; Klier M; Bink K; Kremer M; Raffeld M; Fend F; Quintanilla-Martinez L
Haematologica; 2012 Sep; 97(9):1422-30. PubMed ID: 22315488
[TBL] [Abstract][Full Text] [Related]
6. Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.
Deng M; Xu-Monette ZY; Pham LV; Wang X; Tzankov A; Fang X; Zhu F; Visco C; Bhagat G; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Hagemeister F; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Liu P; Young KH
Mol Cancer Res; 2021 Feb; 19(2):249-260. PubMed ID: 33154093
[TBL] [Abstract][Full Text] [Related]
7.
Eskelund CW; Dahl C; Hansen JW; Westman M; Kolstad A; Pedersen LB; Montano-Almendras CP; Husby S; Freiburghaus C; Ek S; Pedersen A; Niemann C; Räty R; Brown P; Geisler CH; Andersen MK; Guldberg P; Jerkeman M; Grønbæk K
Blood; 2017 Oct; 130(17):1903-1910. PubMed ID: 28819011
[TBL] [Abstract][Full Text] [Related]
8. Mantle Cell Lymphoma With MYC Rearrangement: A Report of 17 Patients.
Hu Z; Medeiros LJ; Chen Z; Chen W; Li S; Konoplev SN; Lu X; Pham LV; Young KH; Wang W; Hu S
Am J Surg Pathol; 2017 Feb; 41(2):216-224. PubMed ID: 27776009
[TBL] [Abstract][Full Text] [Related]
9. Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features.
Aukema SM; Croci GA; Bens S; Oehl-Huber K; Wagener R; Ott G; Rosenwald A; Kluin PM; van den Berg E; Bosga-Bouwer AG; Hoogendoorn M; Hoster E; Bittmann I; Nagel I; Murga Penas EM; Kreuz M; Bausinger J; Belder W; Oschlies I; Dyer MJS; Jayne S; Siebert R; Klapper W
Virchows Arch; 2021 Jul; 479(1):133-145. PubMed ID: 33528622
[TBL] [Abstract][Full Text] [Related]
10. Characterization of genetic changes in MCL by interphase FISH on tissue sections.
Sander B; Wallblom A; Ekroth A; Porwit A; Kimby E
Leuk Lymphoma; 2007 Jul; 48(7):1344-52. PubMed ID: 17613764
[TBL] [Abstract][Full Text] [Related]
11. Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study.
Schiefer AI; Kornauth C; Simonitsch-Klupp I; Skrabs C; Masel EK; Streubel B; Vanura K; Walter K; Migschitz B; Stoiber D; Sexl V; Raderer M; Chott A; da Silva MG; Cabecadas J; Müllauer L; Jäger U; Porpaczy E
Medicine (Baltimore); 2015 Dec; 94(52):e2388. PubMed ID: 26717387
[TBL] [Abstract][Full Text] [Related]
12.
Wang L; Tang G; Medeiros LJ; Xu J; Huang W; Yin CC; Wang M; Jain P; Lin P; Li S
Haematologica; 2021 May; 106(5):1381-1389. PubMed ID: 32273477
[TBL] [Abstract][Full Text] [Related]
13. Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis.
Mossafa H; Damotte D; Jenabian A; Delarue R; Vincenneau A; Amouroux I; Jeandel R; Khoury E; Martelli JM; Samson T; Tapia S; Flandrin G; Troussard X
Leuk Lymphoma; 2006 Sep; 47(9):1885-93. PubMed ID: 17065002
[TBL] [Abstract][Full Text] [Related]
14. Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP.
Shen L; O'Shea JM; Kaadige MR; Cunha S; Wilde BR; Cohen AL; Welm AL; Ayer DE
Proc Natl Acad Sci U S A; 2015 Apr; 112(17):5425-30. PubMed ID: 25870263
[TBL] [Abstract][Full Text] [Related]
15. p53 and mdm2 in mantle cell lymphoma in leukemic phase.
Solenthaler M; Matutes E; Brito-Babapulle V; Morilla R; Catovsky D
Haematologica; 2002 Nov; 87(11):1141-50. PubMed ID: 12414343
[TBL] [Abstract][Full Text] [Related]
16. CD5-negative blastoid variant mantle cell lymphoma with complex CCND1/IGH and MYC aberrations.
Seok Y; Kim J; Choi JR; Kim YR; Park SJ; Kim SJ; Song J; Lee KA
Ann Lab Med; 2012 Jan; 32(1):95-8. PubMed ID: 22259787
[TBL] [Abstract][Full Text] [Related]
17. p53 expression in large B-cell lymphomas with MYC extra copies and CD99 expression in large B-cell lymphomas in relation to MYC status.
Richardson AI; Zhang D; Woodroof J; Cui W
Hum Pathol; 2019 Apr; 86():21-31. PubMed ID: 30496802
[TBL] [Abstract][Full Text] [Related]
18. Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.
Le Bris Y; Magrangeas F; Moreau A; Chiron D; Guérin-Charbonnel C; Theisen O; Pichon O; Canioni D; Burroni B; Maisonneuve H; Thieblemont C; Oberic L; Gyan E; Pellat-Deceunynck C; Hermine O; Delfau-Larue MH; Tessoulin B; Béné MC; Minvielle S; Le Gouill S
Hematol Oncol; 2020 Oct; 38(4):446-455. PubMed ID: 32472610
[TBL] [Abstract][Full Text] [Related]
19. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network.
Aukema SM; Hoster E; Rosenwald A; Canoni D; Delfau-Larue MH; Rymkiewicz G; Thorns C; Hartmann S; Kluin-Nelemans H; Hermine O; Dreyling M; Klapper W
Blood; 2018 Jan; 131(4):417-420. PubMed ID: 29196411
[TBL] [Abstract][Full Text] [Related]
20. Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations.
Alidousty C; Baar T; Martelotto LG; Heydt C; Wagener S; Fassunke J; Duerbaum N; Scheel AH; Frank S; Holz B; Binot E; Kron A; Merkelbach-Bruse S; Ihle MA; Wolf J; Buettner R; Schultheis AM
J Pathol; 2018 Sep; 246(1):67-76. PubMed ID: 29885057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
